What Is SLU-PP-332?

1. How does SLU-PP-332 work?

Estrogen-related receptors help regulate genes involved in cellular energy production. Activating them can change the machinery that muscle uses to consume oxygen and process fuel. “Pan-ERR agonist” means that SLU-PP-332 activates all three receptor types. It showed its greatest potency at ERRα in the original cell assays.

The receptor name causes confusion. ERRs differ from classical estrogen receptors and do not bind the body’s estrogens in the same way. Calling this an estrogen drug, or predicting testosterone suppression from its name, skips the biology. Human hormone measurements would still be needed to establish endocrine effects.

The word “mimetic” also has limits. Researchers can test whether a drug reproduces particular exercise responses. That does not establish the full set of adaptations from running, lifting, practicing a skill or progressively increasing training load.

2. SLU-PP-332 benefits: what the research covers

The publications span several research programs. Here are the primary papers behind the main claims, including developments beyond the first endurance headlines.

A ClinicalTrials.gov search returned no records for SLU-PP-332 on September 21, 2026. The literature search also found no published human treatment trial. Searches under a research name cannot exclude an unpublished program or a study registered under another identifier.

3. Endurance: what “70% longer” means

In Billon and colleagues’ 2023 experiment, sedentary mice received SLU-PP-332 for seven days before a treadmill test to exhaustion. Compared with vehicle-treated controls, they ran approximately 70% longer and 45% farther. Researchers also found changes toward a more oxidative muscle phenotype, including increased type IIa fibers.

Those percentages describe two different endpoints in a specific treadmill protocol. Neither is a measured change in human VO₂ max, race time or cycling power. An exhaustion test also differs from completing a fixed distance as fast as possible.

For a trained athlete, the unanswered question is whether a treatment adds anything beyond existing adaptations. That requires a study in trained people, with comparable training, a control group and a defined performance test. A watch reporting a higher estimated VO₂ max after several weeks cannot supply that comparison.

4. Fat loss: less fat gain is a different result

The metabolic-syndrome paper included a 28-day experiment in male mice with diet-induced obesity. Figure 3 reports seven mice per group. At the endpoint, treated mice weighed about 12% less than controls. Controls gained roughly 5 g of fat; treated mice gained less than 0.5 g. Researchers reported increased energy expenditure without a change in food intake or locomotor activity.

“Ten times less fat gain” describes the accumulation during that experiment. It does not mean that animals lost 90% of their existing fat. Likewise, a difference between groups at the endpoint should not be presented as a 12% reduction from each animal’s starting weight.

For someone planning a cut, baseline-to-final fat mass, lean mass and performance would all matter. Reduced fat accumulation during high-fat feeding cannot by itself predict those outcomes in a lean person eating below maintenance. There is no defensible human weight-loss percentage to place beside these mouse results.

5. Oral SLU-PP-332 versus SLU-PP-915

The January 2026 SLU-PP-915 paper, first published online in December 2025, explicitly describes SLU-PP-332 as lacking oral bioavailability. The investigators tested a chemically distinct molecule, SLU-PP-915, which retained exercise-mimetic activity after oral administration in mice.

That finding cannot validate SLU-PP-332 capsules. A new formulation would need its own absorption measurements and outcome data. Milligrams printed on a bottle describe the claimed contents; bioavailability describes how much reaches circulation.

The 2026 chemical-optimization study is another sign of work still underway. Okda and colleagues modified the SLU-PP-332 structure to investigate receptor activity, solubility and metabolic stability. Some analogues improved selected properties. This was medicinal chemistry research, with cell assays and modeling, rather than evidence that a retail formulation works in people.

6. Dosage, cycles and half-life

No clinically validated human dose or cycle emerged from the evidence reviewed here. The mouse metabolic experiment used 50 mg/kg twice daily by intraperitoneal injection, a route into the abdominal cavity. That is study context, not a human dosing instruction. It cannot establish an oral or subcutaneous regimen.

Converting an animal dose by body size leaves absorption, clearance, active metabolites and toxicity unresolved. A lower number copied from a seller’s chart does not resolve them either. Establishing a useful dose requires measuring exposure alongside benefits and adverse events.

A reliable human elimination half-life is also unavailable. The metabolic paper cites measurable mouse plasma and muscle exposure six hours after injection. A concentration at one time point cannot establish a six-hour half-life, how often to dose, or how long an effect lasts.

The 2026 Möller study used human liver preparations to generate and identify metabolites. “Human” here describes the biological material used in a laboratory. No participant swallowed or received the compound, so the experiment cannot determine whole-body clearance or a washout period.

7. Side effects, heart research and long-term safety

There are no dependable human side-effect rates from controlled treatment trials in the evidence reviewed. Claims of “no side effects” and lists assigning frequencies to headaches, nausea or fatigue need a human dataset behind them. Personal reports lack a reliable denominator and often leave product identity uncertain.

The Circulation heart-failure study found improved cardiac function and survival with ERR agonists in mice exposed to pressure overload. It also examined mitochondrial function and fuel metabolism. Those results support further cardiac research; they cannot establish cardiovascular safety during self-directed use by a healthy athlete.

The available studies do not settle long-term cancer risk, reproductive effects, pregnancy safety or interactions with other drugs. The absence of a reported problem in a short animal experiment cannot provide a numerical risk estimate for years of human exposure.

Product testing answers a separate question. Even accurate identity and purity results cannot establish clinical safety, effective absorption or an appropriate dose. For injections, chemical purity alone also leaves sterility unresolved.

8. SLU-PP-332, MOTS-c and GLP-1 stacks

MOTS-c is a mitochondrial-derived peptide with a different research history. SLU-PP-332 directly activates ERRs. Shared language about mitochondria or endurance does not make the compounds interchangeable, and evidence for one cannot validate the other.

For combinations with tirzepatide or retatrutide, this review found no controlled human evidence establishing added benefit or safety. The proposed appeal is increased expenditure alongside changes in appetite and metabolism. That remains a hypothesis for a combination trial.

A lower scale weight would not establish that the added compound preserved muscle. That claim needs body-composition measurements, strength or functional outcomes, and a comparison with the same weight-loss treatment alone. Changing diet, training and several drugs together also makes it difficult to attribute either improvement or harm.

9. Tested sport and the next evidence to watch

WADA’s rules cover non-approved pharmacological substances even when individual names are absent. A missing search result is not permission to use a research compound in tested sport. Athletes should confirm the applicable classification with their anti-doping organization.

Detection research is already underway. Avliyakulov and colleagues’ 2026 paper identified SLU-PP-332 metabolites in human liver preparations for potential doping-control use. It does not establish a safe or reliable time window for avoiding detection.

For future updates, look for a registered human study specifying the exact molecule and formulation, measured drug exposure, adverse-event monitoring and a prespecified outcome. Oral absorption data would answer one question. A controlled improvement in human endurance or fat mass would answer another.

10. SLU-PP-332 FAQ

• Is SLU-PP-332 a peptide?

  No. SLU-PP-332 is a synthetic small molecule that activates estrogen-related receptors. Being sold alongside peptides does not make it a peptide, and peptide reconstitution instructions do not establish a suitable formulation.

• Does SLU-PP-332 help with weight loss?

  Mouse research found metabolic changes and reduced fat accumulation. No published human treatment trial identified in this review establishes how much weight a person would lose, whether muscle would be preserved, or whether weight would return after stopping.

• Does oral SLU-PP-332 work?

  Human efficacy has not been established. A January 2026 paper explicitly describes SLU-PP-332 as lacking oral bioavailability. Its positive oral mouse results concern the chemically distinct SLU-PP-915, not SLU-PP-332 capsules.

• What is the recommended SLU-PP-332 dosage?

  There is no clinically validated human dose or cycle for fat loss or performance. Animal injection doses cannot establish a human capsule, subcutaneous injection or pre-workout schedule.

• What is the half-life of SLU-PP-332?

  A dependable human elimination half-life has not been established. Finding a compound in mouse blood or muscle six hours after injection does not mean it has a six-hour half-life.

• Does SLU-PP-332 affect estrogen or testosterone?

  Estrogen-related receptors are distinct from classical estrogen receptors. The name does not establish an estrogen-raising effect, testosterone suppression or a need for post-cycle therapy. Human hormonal effects remain insufficiently characterized.

• Can SLU-PP-332 be stacked with tirzepatide or retatrutide?

  This review found no controlled human evidence establishing the safety or added benefit of either combination. Different mechanisms do not demonstrate better fat loss, muscle retention or a safe dose ratio.

• Is SLU-PP-332 approved for human use?

  The evidence reviewed through September 21, 2026 describes SLU-PP-332 as a preclinical research compound, with no established approved human treatment. A research-use label or a seller's dosing chart is not a drug approval.

11. Sources